普罗布考联合阿托伐他汀对脑梗死并认知障碍患者的影响研究

Impact of Probucol and Atorvastatin on Cerebral Infarction Patients Complicated with Cognitive Impairment

目的:探讨普罗布考联合阿托伐他汀对脑梗死并认知障碍患者的预后及血清Hcy、hs-CRP和血脂水平的影响。方法:选取脑梗死患者163例为观察对象,随机分为观察组患者87例和对照组患者76例,对照组给予常规治疗+阿托伐他汀治疗,观察组给予常规治疗+普罗布考联合阿托伐他汀治疗,分别于治疗前、治疗90天后行NIHSS,MMSE和ADL评分,并于治疗前和治疗90天后检测两组患者血清Hcy、hs-CRP和血脂(TC,TG,LDL-C,HDL-C)水平并进行比较。结果:两组患者治疗90天后,临床症状较治疗前好转,观察组在治疗90天后NIHSS、MMSE和ADL评分方面明显优于对照组,差异具有统计学意义(P<0.05);临床疗效方面比较,治疗90天后观察组有效率为93.1%,明显优于对照组的84.2%,两组比较差异具有统计学意义(P<0.05),且观察组患者的显效率(52.9%)也高于对照组(36.8%),两组比较差异具有统计学意义(P<0.05);治疗90天后,两组患者血清Hcy、hs-CRP和血脂(TC,TG,LDL-C,HDL-C)明显改善,且观察组患者改善优于对照组,两组比较差异具有统计学意义(P<0.05)。结论:普罗布考联合阿托伐他汀可显著改善脑梗死并认知障碍患者的临床症状,并可调控血清Hcy、hs-CRP和血脂水平。

Objective： To investigate the impact of probucol and atorvastatin on patients with acute cerebral infarction complicated withcognitive impairment.Methods：163 ischemic stroke patients were collected in this study,76 patients in control group and 87 patients in treatment group.Patients in control group were treated with routine therapy ＋ atorvastatin,patients in treatment group were treated with the routine treatment ＋ atorvastatin＋ probueol for 90 days.The NIHSS, MMSE and ADL score were used to evaluate the recovery of the two groups after 90 days.The levels of Hcy,hs-CRP,TC,TG,LDL-C and HDL-C were detected after 90 days,and the adverse reactions were recorded in two groups.Results：After 90 days of treatment,the NIHSS,MMSE and ADL score of patients in the treatment group was significantly better than that in control group （P〈O.O5）;the total efficiency and the recovery rate of treatment group significantly higher than the control group （P〈0.05）;Hcy,hs-CRP,TC,TG,LDL-C and HDL-C showed that the treatment group were significantly better than the control group （P〈0.05）;two groups of adverse reactions were no significant difference （P〈O.O5）.Conclusion：Probucol combined with atorvastatin is safe and effective for patients with cerebral infarction complicated withcognitive impairment.